|
PARIS, November 25th, 2011 Pharmaleads announces the entry in Phase 2 of PL37, the lead compound of a new class of painkillers, after a successful Phase 1 including initial efficacy testing
SANTA FE, New Mexico, United States, 2nd - 7th October , 2011 Pharmaleads abstracts at the Toxins 2011 and 48th IBRCC meetings
PARIS, December 2010 « Innovation et Industrie » publishes its march issue an article "Biotech" and "big pharma" à la recherche du modèle gagant by Michel Wurm MD, Pharmaleads’Corporate Development Director.
ATLANTA, November 1st-5th, 2010 Pharmaleads to present recent data on alternative quantification methods of Botulinum toxins at the 47th Annual Interagency Botulism Research Coordinating Commitee (IBRCC) meeting
PARIS, November 17th, 2008 Pharmaleads and Debiopharm sign licence agreement
PARIS, October 1st, 2008 Pharmaleads' lead candidate for pain, PL37, enters Phase I
VIENNA, August 31th-September 4th,2008 Pharmaleads Poster on PL37 presented at the ISMC 2008 meeting
BAVENO, ITALY, June 12-14th,2008 Pharmaleads Poster on botulinum Toxin A exosites presented at "Toxin 2008 Meeting"
LONDON 2008 April 7-8th: Pharmaleads EzyBot presentation at "Water Contamination Emergencies"
PARIS, January 2007 Pharmaleads on TV
PARIS, November 24th 2006 Bertrand Delanoe, the mayor of Paris inaugurated the new labs of Pharmaleads in the Paris BioPark
PARIS, August 27th 2006 Michel Wurm M.D to head Pharmaleads Development effort
PARIS, May 16th 2006 Pharmaleads joins MediTech Health Cluster
PARIS, April 5th 2006 New Very High Fluorescence Library of Peptide Substrates for Protease HTS
.To receive our new Press Releases please register with the following form:
|
